Using Tocilizumab in Hematologic Malignant Patients with Severe COVID-19 Infection - Case Series Report.

Chunlan FuYuanyuan ZhuWeijia HuangYi LuoYongxian HuHe HuangJie Sun

Published in: Infection and drug resistance (2024)

Tocilizumab can improve the outcome of severe COVID-19 infection in hematologic malignancy patients with severe immunodeficiency without severe adverse reactions.

Keyphrases

early onset
rheumatoid arthritis
drug induced
juvenile idiopathic arthritis
rheumatoid arthritis patients
disease activity